Information Provided By: 
Fly News Breaks for January 22, 2020
AZN, AMRN
Jan 22, 2020 | 08:25 EDT
Oppenheimer analyst Leland Gershell raised his price target for Amarin (AMRN) to $13 from $8 as AstraZeneca (AZN) appears to have no plans to ever launch Epanova. The analyst notes that AstraZeneca has announced plans to close its large CV outcomes trial of Epanova based on a recommendation from the trial's independent data monitoring committee which determined that STRENGTH would be unlikely to demonstrate benefit in the mixed dyslipidemia patient population at increased risk of CV disease. Gershell has an Outperform rating on Amarin's shares.
News For AMRN;AZN From the Last 2 Days
AZN
Apr 18, 2024 | 09:41 EDT
Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).
